Create new account

Publikacje

-------

Publikacje w recenzowanych czasopismach

Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, Valentin J-P, Van Goethem F, Weaver R, Birk B, Boyer S, Caloni F, Chen A, Corvi R, Cronin M, Daneshian M, Ewart L, Fitzgerald R, Hamilton G, Hartung T, Kangas J, Kramer N, Leist M, Marx U, Polak S, Rovida C, Testai E, van der Water B, Vulto P, Steger-Hartmann T. Optimizing drug discovery by Investigative Toxicology: Current and future trendsALTEX - Alternatives to animal experimentation, 2019, 36, 2; doi:https://doi.org/10.14573/altex.1808181.

Chetty M, Johnson TN, Polak S, Salem F, Doki K, Rostami-Hodjegan A. Physiologically based pharmacokinetic modelling to guide drug delivery in older peopleAdvanced Drug Delivery Reviews, 2018, doi:https://doi.org/10.1016/j.addr.2018.08.013.

Tuszyński PK, Szlęk J, Polak S, Jachowicz R, Mendyk A. In Vitro-In Vivo Correlation (IVIVC): From Current Achievements Towards the Future.Dissolution Technologies, 2018, doi:dx.doi.org/10.14227/DT250318P20.

Patel N, Wiśniowska B, Polak S. Virtual thorough QT (TQT) trial - extrapolation of in vitro cardiac safety data to in vivo situation using multi-scale physiologically based ventricular cell-wall model exemplified with tolterodine and fesoterodineAAPS J, 2018, 20:83.

Tylutki Z, Mendyk A, Polak S. Physiologically Based Pharmacokinetic - Quantitative Systems Toxicology and Safety (PBPK-QSTS) Modeling Approach Applied to Predict the Variability of Amitriptyline Pharmacokinetics and Cardiac Safety in Populations and in IndividualsJournal of Pharmacokinetics and Pharmacodynamics, 2018, https://doi.org/10.1007/s10928-018-9597-6.

Mikkelsen C, Jornil J, Andersen L, Hasselstrom J, Polak S. Utilizing Postmortem Drug Concentrations in Mechanistic Modeling and Simulation of Cardiac Effects: A Proof of Concept Study with MethadoneToxicology Mechanisms and Methods, 2018, doi: https://doi.org/10.1080/15376516.2018.1475537.

Wiśniowska B, Polak S. Drug - physiology interaction and its influence on the QT prolongation - mechanistic modeling studyJournal of Pharmacokinetics and Pharmacodynamics, 2018, doi: https://doi.org/10.1007/s10928-018-9583-z.

Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, Hanna D. Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug developmentJournal of Pharmacokinetics and Pharmacodynamics, 2018, doi:https://doi.org/10.1007/s10928-018-9580-2.

Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, Hermann D, Polak S. Towards bridging translational gap in cardiotoxicity prediction: An application of Progressive Cardiac Risk Assessment Strategy in TdP risk assessment of MoxifloxacinAAPS J, 2018, 20: 47.

Polak S, Wisniowska B, Mendyk A, Paclawski A, Szlek J. Quantitative assessment of the physiological parameters influencing QT interval response to medication: application of computational intelligence tools. Computational and Mathematical Methods in Medicine, 2018, Article ID 3719703.

Tuszynski PK, Polak S, Jachowicz R, Mendyk A. From in vitro-in vivo relationship (IVIVR) towards in vitro-in vivo extrapolation (IVIVE): A case study of pulmonary delivery systems. Dissolution Technologies, 2017, 24(4): 32-35.

Tylutki Z, Mendyk A, Polak S. Mechanistic PBPK model of the heart accounting for inter-individual variability - development and performance verification. Journal of Pharmaceutical Sciences, 2017, In press, accepted manuscript.

Patel N, Wisniowska B, Jamei M, Polak S. Real patient and its virtual twin: Application of quantitative systems toxicology modelling in the cardiac safety assessment of citalopram. AAPS J, 2017, Accepted for publication.

Wisniowska B, Lisowski B, Kulig M, Polak S. Drugs interaction at hERG channel - in vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Journal of Applied Toxicology, 2017, Accepted for publication.

Wisniowska B, Tylutki Z, Polak S. Humans Vary, So Cardiac Models Should Account For That Too!. Friontiers in Physiology, 2017, 8: 700.

Wisniowska B, Tylutki Z, Polak S. Thorough QT (TQT) studies: Concordance with torsadogenesis and evolving cardiac safety testing paradigm. Drug Discovery Today, 2017, 22(10): 1460-1465.

Tylutki Z, Polak S. A four-compartment PBPK heart model accounting for cardiac metabolism - model development and applicationNature Scientific Reports, 2017, Scientific Reports 7, Article number: 39494.

Abbasi M, Patel N, Small B, Jamei M, Polak S. Early assessment of pro-arrhythmic risk of drugs using the in vitro data and single cell based in silico models: proof of concept Toxicology Mechanisms and Methods, 2017, 27(2):88-99.

Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and QT prolongation Current Pharmacology Reports, 2016,2(6): 339-344.

Wisniowska B, Polak S. So am I or am I not proarrhythmic? Comparison of various classifications of drugs TdP propensity. Drug Discovery Today, In Press, Corrected Proof.

Wisniowska B, Polak S. Virtual clinical trial towards polytherapy safety assessment – combination of PBPK/PD based modelling and simulation approach with DDIs involving terfenadine as an example. Journal of Pharmaceutical Sciences, 2016,105(11): 3415-3424.

Tylutki Z, Polak S, Wisniowska B. Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling & Simulations. Current Pharmacology Reports, 2016,2(14): 171-177.

Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacology and Toxicology, 2016, 17(12).

Tylutki Z, Polak S. The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study. Bio-Algorithms and Med-Systems, 2016, 12(1):33-38.

Badyra B, Lisowski B, Polak S, Kudolo J, Wiśniowska B. How in vitro influences in silico utilized for the prediction of in vivo — pilot study of the drug-induced pro-arrhythmic potency prediction. Folia Medica Cracoviensia, 2015,LV(4): 5-19.

Mendyk A, Güres A, Jachowicz R, Szlęk J, Polak S, Wisniowska B, Kleinebudde P. From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks (ANNs) and Genetic Programming (GP). Computational and Mathematical Methods in Medicine, 2015, Article ID 863874.

Culen M, Tuszyński PK, Polak S, Jachowicz R, Mendyk A, Dohnal J. Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from ‘‘Golem’’: A Novel Apparatus). BioMed Research International, 2015, Article ID 328628.

Polak S, Pugsley MK, Stockbridge N, Garnett C, Wisniowska B. Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS Journal, 2015; 17(4): 1025-1032.

Tylutki Z, Polak S. Plasma vs. heart tissue concentration in humans – literature data analysis of drugs distribution. Biopharmaceutics and Drug Disposition, 2015; 36(6): 337–351.

Glinka A, Polak S. QTc modification after risperidone administration – insight into the mechanism of action with use of the modeling and simulation at the population level approachToxicology Mechanisms and Methods, 2015; 25(4): 279-286.

Wisniowska B, Mendyk A, Szlęk J, Kołaczkowski M, Polak S. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents. Journal of Applied Toxicology, 2015; 35(9): 1030–1039.

Mishra H, Polak S, Jamei M, Rostami-Hodjegan A. Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.  CPT Pharmacometrics Syst. Pharmacol., 2014; 3, e130.

Fijorek K, et al. Model of the distribution of diastolic left ventricular posterior wall thickness in healthy adults and its impact on the behavior of a string of virtual cardiomyocytes. Journal of Cardiovascular Translational Research, 2014; 7(5): 507-517.

Fijorek K, Püsküllüoglu M, Tomaszewski R, Tomaszewska D, Glinka A, Polak S. Serum potassium, sodium and calcium levels in healthy individuals – literature review and data analysis. Folia Medica Cracoviensia, 2014; LIV(1): 53-70.

Glinka A, Polak S. The Effects of Six Antipsychotic Agents on QTc - an attempt to mimic clinical trial through simulation including variability in the population. Computers in Biology and Medicine, 2014; 7:20-26.

Wisniowska B, Mendyk A, Fijorek K, Polak S. Computer-based prediction of the drug proarrhythmic effect - problems, issues, known and suspected challenges Europace, 2014, 16:724-735.

Polak S, Wisniowska B, Fijorek K, Glinka A, Mendyk A. In vitro - in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014; 19:275-281.

Glinka A, Polak S. An analysis of cardiomyocyte electrophysiology in the presence of hERG gene mutations. Bio-Algorithms and Med-Systems, 2013; 9(3):135-140.

Fijorek K, Püsküllüoglu M, Polak S. Circadian models of serum potassium, sodium and calcium concentrations in healthy individuals, and their application to cardiac electrophysiology simulations at individual levelComputational and Mathematical Methods in Medicine, 2013; Article ID 429037, 8 pages, 2013. doi:10.1155/2013/429037.

Mendyk A, Tuszyński P, Polak S, Jachowicz R. In vitro-in vivo relationship (IVIVR) generalized model based on artificial neural networksJournal of Drug Design, Development and Therapy, 2013;7:223-232.

Fijorek K, Patel N, Klima Ł, Stolarz-Skrzypek K, Kawecka-Jaszcz K, Polak S. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case studyTheoretical Biology and Medical Modelling, 2013;10:7.

Polak S. In vitro to human in vivo translation – pharmacokinetics and pharmacodynamics of quinidineALTEX, 2013;3(30):309-318.

Glinka A, Polak S. Wild type and K897T polymorphisms of the hERG gene: modeling the AP in CaucasiansBioinformation, 2012;8(22):1062-1065.

Polak S, Wisniowska B, Glinka A, Polak M. tox-database.net - data describing the chemicals triggered in vitro cardiac ionic channels inhibitionBMC Pharmacology and Toxicology, 2012;13(6).

Wisniowska B, Mendyk A, Fijorek K, Glinka A, Polak S. Predictive model for the L-type channel inhibition - multichannel block in QT prolongation risk assessmentJournal of Applied Toxicology, 2012;32(10):858-866.

Polak S, Fijorek K. Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment - analysis of the age - cardiomyocytes electric capacitance dependence. Journal of Cardiovascular Translational Research, 2012;5(3):321-332.

Polak S, Wisniowska B, Glinka A, Fijorek K, Mendyk A. Slow delayed rectifying potassium current (IKs) – analysis of the in vitro inhibition data and predictive model developmentJournal of Applied Toxicology, 2013;33(8):723-739.

Polak S, Fijorek K, Glinka A, Wisniowska B, Mendyk A. Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessmentToxicology Mechanisms and Methods, 2012;22(1):31-40.

Fijorek K, Fijorek D, Wisniowska B, Polak S. BDTcomparator: a program for comparing binary classifiersBioinformatics,2011;27(24):3439-3440.

Fijorek K, Fijorek D. The effectiveness of best subset variable selection in Firth logistic regressionApplied Informatics Methods, 2012;2(27):15-24.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. The open-access dataset for in silico cardiotoxicity prediction systemBioinformation, 2011;6(6):244-245.

Polak S, Wisniowska B, Ahamadi M, Mendyk A. Prediction of the hERG potassium channel inhibition potential with use of Artificial Neural NetworksApplied Soft Computing, 2011;11(2):2611-2617.

Wisniowska B, Mendyk A, Polak M, Szlek J, Polak S. RandomForest based assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing. Bio-Algorithms and Med-Systems, 2010;6(12):131-136.

Wisniowska B, Polak S. hERG in vitro interchange factors - development and verificationToxicology Mechanisms and Methods, 2009;19(4):278-284.

Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs cardiotoxic propertiesJournal of Applied Toxicology, 2009;29(3):183-206.

-------

Rozdziały książek / Materiały konferencyjne / Prezentacje konferencyjne

Barbara Wisniowska, Sebastian Polak, Jerzy Brandys. Extrapolating factors for different in vitro hERG systems. Central European Congress of Life Science EUROBIOTECH 2008, Kraków 17-19.10.2008; Acta Biochimica Polonica 2008, vol. 55 suppl. 4

Sebastian Polak, Barbara Wisniowska, Jerzy Brandys. Modelling and simulation in the drug discovery, research and development. Toxicity prediction. 5th German-Polish Symposium “New Challenges for Pharmaceutical Sciences”, Poznan 15-16.05.2009

Barbara Wisniowska, Sebastian Polak, Jerzy Brandys. Bayesian classification methods for proarrhythmic liability prediction. 5th German-Polish Symposium “New Challenges for Pharmaceutical Sciences”, Poznan 15-16.05.2009

Sebastian Polak, Barbara Wisniowska, Jerzy Brandys. Decision trees algorithms for the in silico prediction of hERG potassium channels inhibition (in polish). Polish Society of Toxicology Workshop “New trends in toxicology”, Lodz 1-2.06.2009

Barbara Wisniowska, Sebastian Polak. Cardiotoxicity prediction algorithms. 1st International Workshop Computational Pharmacy, Krakow 19.06.2009

Sebastian Polak. Modelling and simulations in modern pharmacy – bridging regulatory bodies, academia and industry. 3rd BBBB-Bosphorus International Conference on Pharmaceutical Sciences, Antalya, Turkey 26-28.10.2009; European Journal of Pharmaceutical Sciences 2009, vol. 38, Issue 1, Supplement

Sebastian Polak, Barbara Wisniowska, Malidi Ahamadi, Aleksander Mendyk. Prediction of the hERG potassium channel inhibition potential with use of the artificial neural networks. 14th Online World Conference on Soft Computing in Industrial Applications (WSC14), 17-29.11.2009

Barbara Wisniowska, Aleksander Mendyk, Milosz Polak, Jakub Szlek, Sebastian Polak. RandomForest based assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing (polish/english). MCSB 2010, Krakow 21-22.05.2010

Sebastian Polak, Barbara Wisniowska, Malidi Ahamadi, Aleksander Mendyk. Prediction of the hERG potassium channel inhibition potential with use of the artificial neural networks. Soft Computing in Industrial Applications. Algorithms, Integration and Success Stories. In Advances in Intelligent and Soft Computing vol. 75 Eds. Gao X-Z, Gaspar-Cunha A., Koeppen M., Schaefer G., Wang J. Springer, Berlin 2010.

Sebastian Polak. Combining systems biology and pharmacokinetics - drug cardiotoxicity assessment. 2011 CellML Workshop. Auckland, 11-12.04.2011 (on line presentation).

Sebastian Polak, Barbara Wisniowska, Kamil Fijorek, Anna Glinka, Miłosz Polak, Aleksander Mendyk. ToxComp - in silico platform for the cardiotoxicity assessment – in vitro-in vivo extrapolation. Applied Pharmaceutical Toxicology Workshop; May 18 - 20 2011; San Francisco, CA, USA

Sebastian Polak, Aleksander Mendyk. Computational toxicology. In silico assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing. Chemaxon 2011 European UGM, Training day and Markush Forum, May 16-19, Budapest, Hungary

Mini-symposium Computational toxicology and pharmacology - in silico drug activity and safety assessment (Saturday, July 2, 11:00) during the 8-th European Conference on Mathematical and Theoretical Biology and Annual Meeting of The Society for Mathematical Biology; June 28 - July 2 2011, Krakow, Poland.

Mini-symposium Computational toxicology - in silico drug safety assessment during the 3rd Annual Predictive Toxicology; 14-16 September 2011; Berlin, Germany.

Polak S. Optimization of the use of information for in vitro and in silico to predict in vivo Computational toxicology - in silico drug safety assessment during the 3rd Annual Predictive Toxicology; 14-16 September 2011; Berlin, Germany.

Polak S, Glinka A, Wisniowska B, Mendyk A. Influence on the physiological parameters on the ADP90 value simulated by human venrticular tissue model. Eurotox 2011, Aug 28-31, Paris, France.

On-line workshop 3rd International Workshop - Computational Pharmacy; 22 September 2011; Krakow, Poland (Internet!). Materiały wideo i graficzne zostaną wkrótce udostępnione.

Konferencja The 16th Online World Conference on Soft Computing in Industrial Applications (WSC16); December 5th - 16th, 2011; INTERNET! Wyniki prac zespołu prezentowane będą w trakcie sesji specjalnej - Special Session on Soft Computing Methods in Pharmaceutical and Medical Sciences.

Polak S, Mishra H. Combining In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-Based Pharmacokinetics (PBPK) with Drug Related Risk Assessment - Cardiotoxicity prediction. 7th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies; January 26th - 27th, 2012; Brussels, Belgium.

Polak S., Wiśniowska B., Polak M., Szlęk J., Glinka A., Fijorek K. Mendyk A., ToxComp 1.2 – an Open Source iv vitro in vivo extrapolation (IVIVE) system for cardiotoxicity prediction with Marvin plugins embedded. ChemAxon UGM Budapest 2012, May 22-23, Budapest.

Polak S. In vitro-in vivo Extrapolation of the Cardiotoxic Effect: Inter-Individual Variability Matters! 11th World Pharma Congress Philadelphia, PA (5-7 of June, 2012).

Mishra H, Jamei M. Rostami-Hodjegan M, Polak S. Model-Based Prediction of Domperidone and Ketoconazole Interaction and its Impact on QTc Prolongation. 21st PAGE meeting; June 5th - tth, 2012; Venice, Italy.

48th EUROTOX Congress odbył się w Sztokholmie w dniach 17-20 czerwca 2012. Wyniki prac zespołu były prezentowane w postaci posterów: "Influence of the physiological parameters on the APD90 value simulated by human ventricular tissue model" and "Electrophysiologically inactive drugs - can we predict their cardiotoxicity?" dyskutowanych w ramach sesji P07 Computational toxicology.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. In silico prediction of the drug overdose consequences at the heart electrophysiology level. Computing in Cardiology; September 9-12, 2012; Krakow, Poland [pobierz pełen tekst].

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. ToxComp ‐ in vitro–in vivo extrapolation system for the drugs proarrhythmic potency assessment. Computing in Cardiology; September 9-12, 2012; Krakow, Poland [pobierz pełen tekst].

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. Modeling and Simulation Approach for Assessing Proarrhythmic Potency of the Non‐cardiological Drugs. Computing in Cardiology; September 9-12, 2012; Krakow, Poland [pobierz pełen tekst].

Mendyk A, Wisniowska B, Fijorek K, Glinka A, Polak M, Polak S. Empirical modeling of the sodium channel inhibition caused by drugs. Computing in Cardiology; September 9-12, 2012; Krakow, Poland [pobierz pełen tekst].

4th Workshop on using Computational Methods in Pharmaceutical Sciences to jednodniowe warsztaty, które odbędą się 8. września 2012 w Krakowie. Warsztaty będą częścią konferencji Computers in Cardiology - CinC 2012. Ich głównym celem jest prezentacja, dyskusja i praktyczne przećwiczenie metod obliczeniowych stosowanych we wczesnej ocenie potencjału kardiotoksycznego leków.

Polak S. In Vitro to Human In Vivo Translation – Proarrhythmic Potency of Dofetilide8th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies January 24th - 25th, 2013 Brussels, Belgium. 

Polak S., Tomaszewska D., Patel N., Jamei M., Rostami-Hodjegan A. Pharmacokinetic (PK) and pharmacodynamic (PD) implications of diurnal variation of gastric emptying and small intestinal transit time for quinidine: A mechanistic simulation. PAGE conference, 11-14 June 2013, Glasgow, Scotland.

Patel N., Jamei M., Rostami Hodjegan A., Polak S. Prediction of QT changes in humans incorporating in vitro data into physiologically based cardiomyocyte cell model - a case study on inhibition of multiple cardiac ion currents by tolterodine and its metabolite. 2013 AAPS Annual Meeting and Exposition. 10-14 November 2013, San Antonio, USA. POSTER T3221. Session Date: Tuesday, November 12, 2013 Session Time: 01:30 pm - 04:30 pm. 

Small B., et al. Pharmacokinetic (PK) and Pharmacodynamic (PD) Implications of Diurnal Variation of Gastric Emptying and Small Intestinal Transit Time for Quinidine Mechanistic Simulation. BSTP 28th Annual Scientific Meeting held jointly with the Safety Pharmacology Society. Thursday 14th and Friday 15th November 2013; Alderley Park, Cheshire, UK.

Glinka A., Wiśniowska B. hERG channel trafficking mutations – their role in the drug triggered arrhythmia. Simulation study. BSTP 28th Annual Scientific Meeting held jointly with the Safety Pharmacology Society. Thursday 14th and Friday 15th November 2013; Alderley Park, Cheshire, UK.

Polak S. Physiological-Based Cardiomyocyte Model: Predicting QT Changes in Humans. 2015 ASCPT Annual Meeting. 03-07 March 2015, New Orleans, USA. Tuesday March 3, QUANTITATIVE SYSTEMS PHARMACOLOGY: MULTISCALE MODEL-BASED DRUG DEVELOPMENT THROUGH INTEGRATING SYSTEMS BIOLOGY AND PHARMACOMETRICS.

Polak S. Simulating cardiac consequences of the genetic variability at the metabolism level with use of middle-out approach and flecainide as an example compound. 2015 ASCPT Annual Meeting. 03-07 March 2015, New Orleans, USA. POSTER SESSION.

Polak S. 13th European International Society for the Study of Xenobiotics (ISSX) Meeting June 22 - 25, 2015 in Glasgow, Scotland.

Polak S. IVIV and/or animal/human translations. EUFEPS Annual Meeting 2015 - System Approaches for Better Medicines and Health. 15-17 June 2015, Geneva, Switzerland. Tuesday June 16, Session II: Drug development - predictive toxicology, predictive translations.

Wiśniowska B. Evaluation of the ability of computational IVIV extrapolation to assess pharmacokinetic (Cmax/AUC) and pharmacodynamic (QTc) consequences of drug-drug interactions with cisapride and clarithromycin as exemplary drugs. EUFEPS Annual Meeting 2015 - System Approaches for Better Medicines and Health. 15-17 June 2015, Geneva, Switzerland. Tuesday June 16, Session II: Drug development - predictive toxicology, predictive translations.

Viceconti M, Henney A, Morley-Fletcher E. in silico Clinical Trials: How Computer Simulation will Transform the Biomedical Industry. Research and Technological Development Roadmap, Avicenna Consortium, Brussels Jan 2016.

Wiśniowska B, Badyra B, Lisowski B, Polak S. To sum or not to sum - how to assess torsadogenic potential of combination of drugs and their active metabolites. In vitro assessment with loratadine and desloratadine as the exemplary drugs. Safety Pharmacology Society, Annual Meeting, 28.09-1.10.2015, Prague, Czech Republic.

Wiśniowska B, Badyra B, Lisowski B, Polak S, Glinka A. Systems pharmacology based approach utilized for prediction of the cardiac consequences of drug-drug interactions. Safety Pharmacology Society, Annual Meeting, 28.09-1.10.2015, Prague, Czech Republic.

Viceconti M, Henney A, Morley-Fletcher E. in silico Clinical Trials: How Computer Simulation will Transform the Biomedical Industry. Research and Technological Development Roadmap, Avicenna Consortium, Brussels Jan 2016.

-------

Raporty techniczne

Polak S, Fijorek K, Püsküllüoğlu M, Glinka A, Tomaszewska D, Tomaszewski R. Literature review of the serum potassium, sodium and calcium levels in healthy individualsTechnical Note, 2013; 001.

-------

Jesteśmy cytowani